PGL 0.00% 82.0¢ prospa group limited.

encouraging human trial data for progen`s pi-88

  1. 635 Posts.
    This is a significant announcement from Progen.
    The stock added 11c (13.8%) today.
    Should see more to come. Spec buy.
    Company Announcement

    Encouraging Human Trial Data for Progen`s PI-88

    HOMEX - Brisbane

    Progen Industries (ASX: PGL, NASDAQ: PGLAF) - Encouraging interim
    clinical trial data on Progen Industries' lead cancer drug, PI-88,
    has just been presented at an international cancer conference. Dr
    Scott Holden, co-investigator on the trial at University of Colorado
    Health Sciences Centre USA, presented data tram the Phase I/II trial
    that shows PI-88 is well tolerated and demonstrates encouraging
    anti-cancer activity in some patients with advanced cancer.

    The conference is organised by the premier European cancer research
    society, the European Organisation for Research and Treatment of
    Cancer (EOPTC) in association with the American Association for
    Cancer Research (AACR) and the American National Cancer Institute

    Dr Holden explained: "This is the first time that scientific data
    from human trials of PI-88 has been presented publicly. We are
    working with patients with very advanced malignancies including
    melanoma and renal-cell carcinoma and we have been very impressed by
    the effects of PI-88. Not only was there little sign of toxicity, but
    progression of advanced cancers in particular patients has also been
    retarded for extended periods. Some patients with advanced melanoma
    have had stable disease over an 8-16 month period and are continuing
    treatment. In one of these patients the size and number of secondary
    lung cancers have reduced after commencing treatment.

    "We will closely monitor patients' improvement and continue providing
    treatment as long as patients continue to positively respond to PI-88
    treatment," he said.

    Dr Robert Don, VP Research and Development at Progen Industries said:
    "This is a very significant milestone for Progen. Our internal
    preclinical animal studies showed that PI-88 retards the growth of
    tumours by both inhibiting new blood vessel growth (angiogenesis) and
    reducing the spread of the disease (metastasis).

    "External validation that PI-88 administered subcutaneously is well
    tolerated and demonstrates anti-tumour activity is extremely
    heartening for the company. However caution should be exercised in
    over interpreting the data at this stage."

watchlist Created with Sketch. Add PGL (ASX) to my watchlist
(20min delay)
Mkt cap ! $135.0M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
2 70554 80.0¢

Sellers (Offers)

Price($) Vol. No.
80.0¢ 244 1
View Market Depth
Last trade - 07.02am 19/05/2022 (20 minute delay) ?
PGL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.